Skip to content
Trial Eligibility
Menu

Clinical Trials Recruiting near New Haven, CT

856 clinical trials have a recruiting site within 25 miles of New Haven, Connecticut, according to ClinicalTrials.gov data processed . The closest recruiting site is within 1 mile of the city center.

Distances are measured from the city center to each site's city, so they are approximate.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Studies enrolling near New Haven

Showing 30 studies, nearest first.
  1. Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

    NCT04239573

    • Observational
    • Ages 50 to 75 years
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    12 sites within 25 mi
  2. Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

    NCT03851445

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    11 sites within 25 mi
  3. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    NCT05929768

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    11 sites within 25 mi
  4. MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

    NCT03072927

    • Observational
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 25 mi
  5. De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    NCT04852887

    • Phase 3
    • Ages 50 to 70 years
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 25 mi
  6. Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

    NCT05987241

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 25 mi
  7. Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

    NCT07421700

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 25 mi
  8. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    NCT03723928

    • Interventional
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  9. Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

    NCT03937635

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  10. Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

    NCT04566328

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  11. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    NCT05174169

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  12. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  13. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  14. Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

    NCT06661720

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  15. Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

    NCT06958328

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  16. Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

    NCT07166406

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  17. Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

    NCT07578116

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  18. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    NCT04181060

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  19. Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

    NCT04205968

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  20. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    NCT04267848

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  21. Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

    NCT05040360

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  22. Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

    NCT05561387

    • Phase 3
    • Ages Any age
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  23. Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

    NCT05642572

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  24. Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

    NCT05806515

    • Phase 2
    • Ages 18 years and older
    • Sex: Male
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  25. The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

    NCT06377852

    • Phase 3
    • Ages 60 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  26. Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

    NCT06475989

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  27. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    NCT06616584

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  28. Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

    NCT04031677

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 25 mi
  29. ATEMPT 2.0: Adjuvant T-DM1 vs TH

    NCT04893109

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 25 mi
  30. Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

    NCT05058651

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 25 mi

By condition

Clinical trials in New Haven by condition

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.